Non-alcoholic fatty liver disease (NAFLD) is an increasingly recognized condition, often associated with obesity and type 2 diabetes. Understanding its pathogenesis, diagnosis, and treatment is crucial for managing this global health concern.
NAFLD is characterized by excessive hepatic fat accumulation not due to alcohol consumption. It is a multifactorial disease, with insulin resistance and metabolic syndrome playing pivotal roles. The 'two-hit' hypothesis suggests that the first 'hit' involves accumulation of triglycerides in the liver, followed by a second 'hit' of increased oxidative stress leading to inflammation and fibrosis.
NAFLD is often asymptomatic and discovered incidentally during imaging studies. Liver function tests may show elevated aminotransferases. Ultrasound, CT, and MRI can detect hepatic steatosis, but liver biopsy remains the gold standard for diagnosing NAFLD and differentiating it from non-alcoholic steatohepatitis (NASH).
Management of NAFLD primarily focuses on lifestyle modifications including weight loss and increased physical activity. Pharmacological interventions are considered for patients with NASH or fibrosis. These include vitamin E, pioglitazone, and more recently, drugs targeting specific pathways involved in NAFLD pathogenesis, such as obeticholic acid and elafibranor. Liver transplantation is considered for end-stage liver disease.
NAFLD is a complex disease with a multifaceted pathogenesis. Its diagnosis often requires a high degree of clinical suspicion and appropriate use of diagnostic modalities. Advanced treatment approaches are being developed, targeting the specific mechanisms involved in the disease process. As our understanding of NAFLD continues to evolve, so too will our approach to its management, promising better outcomes for patients afflicted with this condition.
1.
New Nanoparticles Can Destroy Undruggable Cancer Proteins
2.
Brain MRI Surveillance Alone Helps Preserve Cognition in Small Cell Lung Cancer
3.
NEET SS Counseling 2023: MCC provides information on DNB SS Medical Oncology seats available at ESIC Medical College and Hospital Faridabad.
4.
Belzutifan Plus Pembro Approved for Adjuvant RCC
5.
Using MRD Status to Deescalate Multiple Myeloma Therapy
1.
Diagnosis and Treatment of Follicular Thyroid Cancer: A Comprehensive Guide
2.
Obesity as a major risk factor for cancer
3.
Unraveling the Genetic Mystery of Hereditary Spherocytosis
4.
Advanced Pathways in Oncology for Better Care
5.
Essential Updates in Hematology in Daily Practice
1.
International Conference on Oncology, Cancer Prevention and Public Health
2.
International Conference on Cancer Nursing and Rehabilitation Strategies
3.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
4.
International Conference on Innovations in Critical Care for Oncology and Cardiology
5.
International Symposium on Oncology, Cardiology and Critical Care Innovations
1.
Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC
2.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part I
3.
Understanding Anemia and Its Common Causes
4.
Targeting Oncologic Drivers with Dacomitinib: Further Discussion on Lung Cancer Treatment
5.
Early Cancer Detection Saves Lives
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation